Ovarian cancer has a unique pattern of spread, with the peritoneal cavity being the primary site of disease. Intraperitoneal delivery of chemotherapeutic agents allows for a higher concentration of drug for a more prolonged period of time at the major site of disease, providing a rationale for its use in ovarian cancer. This approach is supported by multiple clinical trials demonstrating an improved outcome for ovarian cancer patients who receive intraperitoneal chemotherapy. This chapter will address issues critical to the administration of intraperitoneal chemotherapy in ovarian cancer including selection of appropriate patients, the fundamentals of intraperitoneal chemotherapy administration, as well as practical guidelines for trouble-shooting commonly encountered problems.
ASJC Scopus subject areas